Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

CS-1008

CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.

DRUG

FOLFIRI

The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).

Trial Locations (3)

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

86259

Mayo Clinic, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY